Antibodies

Anti-Human HLA-DR Antibody, Clone LN3

Mouse monoclonal IgG2b antibody against human, rhesus HLA-DR, unconjugated

Catalog #60164

100 µg 0.5 mg/mL

STEMCELL™ TECHNOLOGIES
Scientists Helping Scientists™ | WWW.STEMCELL.COM
TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713
INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM
FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

Product Description

The LN3 antibody reacts with the HLA-DR antigen, a major histocompatibility complex (MHC) class II antigen encoded within the human leukocyte antigen (HLA) complex on chromosome 6. HLA-DR is a heterodimeric transmembrane glycoprotein composed of one α (36 kDa) and one β (27 kDa) subunit. MHC class II plays a central role in the presentation of antigen-derived peptides to CD4+ T cells, along with CD3/TCR and CD4. HLA-DR is primarily expressed on the surface of antigen presenting cells, including B cells, dendritic cells, monocytes, macrophages, thymic epithelial cells, and activated T cells.

Target Antigen Name:	HLA-DR
Alternative Names:	HLA class II histocompatibility antigen, HLA-DR alpha, HLA-DRA, HLA DRA1, HLA DR1B, HLA DR3B, HLA DRB1, HLA DRB3, HLA DRB4, HLA DRB5, HLADR4B, HLADRA1, HLADRB, Major histocompatibility class II, MHC II, MHC class II, MHC class II antigen DRA, MLRW
Gene ID:	3122/3123
Species Reactivity:	Human, Rhesus
Host Species:	Mouse
Clonality:	Monoclonal
Clone:	LN3
Isotype:	IgG2b, kappa
Immunogen:	Human peripheral blood lymphocytes
Conjugate:	Unconjugated

Applications

Verified:	FC
Reported:	IHC
Special Applications:	This antibody clone has been verified for labeling dendritic cells generated from monocytes in culture using ImmunoCult™-ACF Dendritic Cell Culture Kit (Catalog #10985).

Abbreviations: CellSep: Cell separation; ChIP: Chromatin immunoprecipitation; FA: Functional assay; FC: Flow cytometry; ICC: Immunocytochemistry; IF: Immunofluorescence microscopy; IHC: Immunohistochemistry; IP: Immunoprecipitation; RIA: Radioimmunoassay; WB: Western blotting

Properties

Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide
Purification:	The antibody was purified by affinity chromatography.
Stability and Storage:	Product stable at 2 - 8°C when stored undiluted. Do not freeze. For product expiry date, please contact techsupport@stemcell.com.
Directions for Use:	For flow cytometry the suggested use of this antibody is ≤ 0.5 µg per 1 x 10^6 cells in 100 µL volume. It is recommended that the antibody be titrated for optimal performance for each application.

Data



Flow cytometry analysis of human peripheral blood mononuclear cells (PBMCs) labeled with Anti-Human HLA-DR Antibody, Clone LN3, followed by an anti-mouse IgG2b antibody, PE (filled histogram), or Mouse IgG2b, kappa Isotype Control Antibody, Clone MPC-11 (Catalog #60072), followed by an anti-mouse IgG2b antibody, PE (solid line histogram).

Related Products

For a complete list of antibodies, including other conjugates, sizes and clones, as well as related products available from STEMCELL Technologies, please visit our website at www.stemcell.com/antibodies or contact us at techsupport@stemcell.com.

References

1. Iorgulescu JB et al. (2016) The limited capacity of malignant glioma-derived exosomes to suppress peripheral immune effectors. J Neuroimmunol 290: 103–8. (FC)
2. Leone DA et al. (2016) The phenotypic characterization of the human renal mononuclear phagocytes reveal a co-ordinated response to injury. PLoS One 11(3): e0151674. (FC)
3. Yawata N et al. (2016) Dynamic change in natural killer cell type in the human ocular mucosa in situ as means of immune evasion by adenovirus infection. Mucosal Immunol 9(1): 159–70. (FC)
4. Antonelli LR V et al. (2014) The CD14+CD16+ inflammatory monocyte subset displays increased mitochondrial activity and effector function during acute Plasmodium vivax malaria. PLoS Pathog 10(9): e1004393. (FC)
5. Pennino D et al. (2013) IL-22 suppresses IFN-γ-mediated lung inflammation in asthmatic patients. J Allergy Clin Immunol 131(2): 562–70. (FC)
6. Imamichi H et al. (2012) The CD8+ HLA-DR+ T cells expanded in HIV-1 infection are qualitatively identical to those from healthy controls. Eur J Immunol 42(10): 2608–20. (FA, FC)
7. Dokouhaki P et al. (2010) Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach. Cancer Lett 297(1): 126–36. (FC)
8. Rajesh D et al. (2010) Th1 and Th17 immunocompetence in humanized NOD/SCID/IL2rgammanull mice. Hum Immunol 71(6): 551–9. (FC, PE)
9. Kalyan S & Chow AW. (2009) Linking innate and adaptive immunity: human Vgamma9Vdelta2 T cells enhance CD40 expression and HMGB-1 secretion. Mediators Inflamm 2009: 819408. (FC)
10. Ristich V et al. (2005) Tolerization of dendritic cells by HLA-G. Eur J Immunol 35(4): 1133–42. (FC)
11. Fullen DR & Headington JT. (1998) Factor XIIIa-positive dermal dendritic cells and HLA-DR expression in radial versus vertical growth-phase melanomas. J Cutan Pathol 25(10): 553–8. (IHC)